Vaxart, Inc. (VXRT)

Market Cap	105.91M
Revenue (ttm)	28.70M
Net Income (ttm)	-66.95M
Shares Out	227.95M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,416,034
Open	0.480
Previous Close	0.481
Day's Range	0.460 - 0.493
52-Week Range	0.450 - 1.410
Beta	1.70
Analysts	Buy
Price Target	4.00 (+760.96%)
Earnings Date	Mar 20, 2025

About VXRT

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Steven Lo
• Employees: 109
• Stock Exchange: NASDAQ
• Ticker Symbol: VXRT
• Website: https://vaxart.com

Financial Performance

In 2024, Vaxart's revenue was $28.70 million, an increase of 288.94% compared to the previous year's $7.38 million. Losses were -$66.95 million, -18.82% less than in 2023.

Analyst Forecast

According to one analyst, the rating for VXRT stock is "Buy" and the 12-month stock price forecast is $4.0.

Price Target

$4.0

(760.96% upside)

Analyst Consensus: Buy